KR20090033886A - 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제 - Google Patents

안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제 Download PDF

Info

Publication number
KR20090033886A
KR20090033886A KR1020097002077A KR20097002077A KR20090033886A KR 20090033886 A KR20090033886 A KR 20090033886A KR 1020097002077 A KR1020097002077 A KR 1020097002077A KR 20097002077 A KR20097002077 A KR 20097002077A KR 20090033886 A KR20090033886 A KR 20090033886A
Authority
KR
South Korea
Prior art keywords
antagonist
alkyl
receptor
subject
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097002077A
Other languages
English (en)
Korean (ko)
Inventor
데브라 엘. 플리너
앨런 알. 쉐퍼드
이옥-호우 팽
Original Assignee
알콘 리서치, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알콘 리서치, 리미티드 filed Critical 알콘 리서치, 리미티드
Publication of KR20090033886A publication Critical patent/KR20090033886A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020097002077A 2006-07-25 2007-07-25 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제 Ceased KR20090033886A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83308006P 2006-07-25 2006-07-25
US60/833,080 2006-07-25

Publications (1)

Publication Number Publication Date
KR20090033886A true KR20090033886A (ko) 2009-04-06

Family

ID=38982306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002077A Ceased KR20090033886A (ko) 2006-07-25 2007-07-25 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제

Country Status (11)

Country Link
US (2) US20080025973A1 (https=)
EP (1) EP2068856A2 (https=)
JP (1) JP2009544734A (https=)
KR (1) KR20090033886A (https=)
CN (1) CN101505744A (https=)
AU (1) AU2007279311A1 (https=)
BR (1) BRPI0714593A2 (https=)
CA (1) CA2657480A1 (https=)
MX (1) MX2009000907A (https=)
WO (1) WO2008014338A2 (https=)
ZA (1) ZA200900316B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014329B (zh) 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) * 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
MX2009001457A (es) * 2006-08-08 2009-02-19 Kyorin Seiyaku Kk Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo.
JP5188972B2 (ja) * 2006-08-08 2013-04-24 杏林製薬株式会社 アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
WO2009117335A2 (en) * 2008-03-17 2009-09-24 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
US20120071448A1 (en) * 2009-05-05 2012-03-22 Allergan, Inc. S1P3 Receptor Inhibitors for Treating Conditions of the Eye
US20110039900A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
BR112012006965A2 (pt) * 2009-09-30 2017-08-29 Stiefel Res Australia Pty Ltd Cosmético sob a forma de espuma
CN102146411B (zh) * 2011-01-06 2013-01-02 中国人民解放军第三军医大学第三附属医院 新型双功能抗瘢痕和组织纤维化寡聚核苷酸药物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8107694A (en) * 1993-11-17 1995-06-06 Byk Nederland Bv Use of substituted thiazolidine derivatives in the treatment of raised intraocular pressure
US5545626A (en) * 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
WO2001058468A1 (en) * 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
JP2002332278A (ja) * 2001-05-08 2002-11-22 Human Science Shinko Zaidan Ｅｄｇ受容体拮抗作用を有する複素環誘導体
WO2003092584A2 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
CA2533587A1 (en) * 2002-07-30 2004-02-05 University Of Virginia Patent Foundation Compounds active in sphingosine 1-phosphate signaling
AU2003258433A1 (en) * 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
FR2845003A1 (fr) * 2002-09-30 2004-04-02 Merck Sante Sas Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
CN100418948C (zh) * 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
JP2005247691A (ja) * 2004-03-01 2005-09-15 Toa Eiyo Ltd Ｓ１ｐ３受容体拮抗薬
JP2008522977A (ja) * 2004-12-06 2008-07-03 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−リン酸のアリールアミドアナログ
US8546452B2 (en) * 2005-10-12 2013-10-01 Toa Eiyo Ltd. S1P3 receptor antagonist
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物

Also Published As

Publication number Publication date
US20080025973A1 (en) 2008-01-31
WO2008014338A2 (en) 2008-01-31
CA2657480A1 (en) 2008-01-31
BRPI0714593A2 (pt) 2013-05-07
MX2009000907A (es) 2009-02-04
EP2068856A2 (en) 2009-06-17
ZA200900316B (en) 2010-05-26
JP2009544734A (ja) 2009-12-17
WO2008014338A3 (en) 2008-12-24
US20100183629A1 (en) 2010-07-22
CN101505744A (zh) 2009-08-12
AU2007279311A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
KR20090033886A (ko) 안 질환의 예방 및 치료를 위한 내피 분화 유전자 서브패밀리 3 (ｅｄｇ-3, ｓ1ｐ3) 수용체의 길항제
Tokushige et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
US10149884B2 (en) Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
KR20110004920A (ko) Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
MXPA06007062A (es) Antagonistas cdk2 como antagonistas del factor de transcripcion c-maf de forma corta para el tratamiento de glaucoma.
KR101103141B1 (ko) Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장치료제
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
BR112020015567A2 (pt) medicamento para prevenir ou tratar doença oftálmica associada com neovascularização intraocular e/ou permeabilidade vascular intraocular realçadas
US20100247548A1 (en) Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
Zhan et al. Bunazosin reduces intraocular pressure in rabbits by increasing uveoscleral outflow
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
Mokbel et al. Rho-Kinase Inhibitors as a novel medication for Glaucoma Treatment–A Review of the literature
Virani et al. An Update on Pharmacotherapy of Glaucoma
LEINO et al. Recent developments in anti-glaucoma drug research
CN103402508A (zh) 芳基磺酰胺衍生物的剂量
WO2020166679A1 (ja) 眼圧下降用医薬組成物
Carvalho et al. Topical use of injectable dexmedetomidine in combination with dorzolamide for the intraocular pressure reduction in dogs: a preliminary study
CN112972472A (zh) 化合物a740003在制备治疗年龄相关性黄斑变性的药物中的应用
US20100158897A1 (en) Pai-1 modulators for the treatment of ocular disorders
JP2004189735A (ja) Ｌｉｍキナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131025

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I